Turnstone Biologics Corp. (TSBX)
Turnstone Biologics Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in LA Jolla, CA, US. The stock last traded at $0.35, up 0.00% on the session, giving a market capitalisation of $8.2M. On trailing twelve-month figures it carries a trailing P/E of -0.47, a net margin of 0.0%. Its beta of 1.37 implies it has historically moved more than the broad market.
Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.
Turnstone Biologics Corp. is most often compared with the following Healthcare names: